Navigation Links
Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
Date:10/15/2007

- Data Presented at the American College of Gastroenterology Annual

Scientific Meeting -

PHILADELPHIA, Oct. 15 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that data from the first cohort of patients from an exploratory Phase 2 study evaluating the efficacy and safety of AST-120 in patients with active pouchitis was presented in a poster presentation at the American College of Gastroenterology Annual Scientific Meeting.

"A four-week treatment with AST-120 in patients with active pouchitis led to a significant decrease in symptoms of pouchitis and endoscopy scores in the first ten patients enrolled in the study," said Dr. Bo Shen, principal investigator at the Center for Inflammatory Bowel Disease, Cleveland Clinic. "These results were impressive with 44.4% of the patients achieving clinical remission and 55.6% achieving a clinical response."

"These promising results warrant the further evaluation of AST-120 for the treatment of pouchitis in controlled randomized studies," added Laurent Fischer, M.D. president and CEO of Ocera Therapeutics. "We are encouraged by these findings which further support our strategy of exploring AST-120 as a platform drug with the potential to address multiple gastrointestinal and liver diseases."

Patients who suffer from Ulcerative Colitis often require a resection of the colon to reduce the risk of cancer. A J-pouch is created to collect stools and the pouch often becomes inflamed, a condition known as pouchitis, which is associated with diarrhea, abdominal cramps, fever and dehydration. Pouchitis occurs in up to 40% of patients with a J-pouch and there are no treatments currently approved for this indication. An estimated 80,000 patients in the United States suffer from this condition, which qualifies as Orphan Drug. The current standard of care for pouchitis includes treatment with antibiotics such as ciprofloxacin and metronidazole and relapse is common.

In vitro adsorption studies have demonstrated that AST-120 has a high adsorption capacity for bile acids and bacterial toxins and is expected to protect the intestinal mucosa of the pouch from inflammation.

AST-120 was in-licensed from Kureha Corporation, Japan in 2005. Ocera announced last week that it completed enrollment in FHAST1, the Fistula Healing with AST-120 Phase 3 pivotal trial in Crohn's disease conducted in North America, Europe and Israel. Ocera also recently initiated proof-of-concept trials with AST-120 in Irritable Bowel Syndrome and Hepatic Encephalopathy.

About the Pouchitis Phase 2 Study

The proof-of-concept study conducted under investigator IND at Cleveland Clinic is evaluating 20 patients with active pouchitis treated with open label AST-120, 2 grams tid. The Primary efficacy endpoint is remission as defined by a Pouchitis Disease Activity Index (PDAI) less than 7 points which includes clinical, endoscopy and histology scores. Secondary endpoints include safety, clinical response measured by a decrease of PDAI of a least three points and Global Quality of Life score.

About Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera Therapeutics is based in San Diego and is pursuing the development of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including Pouchitis, Hepatic Encephalopathy, Irritable Bowel Syndrome and Proton Pump Inhibitor-resistant Gastroesophageal Reflux Disease. Ocera Therapeutics has raised $26.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners. Additional information on the Company can be found at http://www.oceratherapeutics.com.

For more information on Pouchitis and Inflammatory Bowel Diseases, visit the Crohn's and Colitis Foundation of America website as http://www.ccfa.org.


'/>"/>
SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):